Ibuprofen B. Braun (Ibuprofen)

Ibuprofen inhibits the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By reducing prostaglandin production, it lowers pain signalling, decreases fever, and limits inflammation at the site of injury.

The specific dose and infusion rate of Ibuprofen B. Braun are determined by the prescribing clinician based on the patient’s age, weight, clinical condition and response. Healthcare professionals follow local guidelines and product labeling to set the appropriate regimen.

Safety data for intravenous ibuprofen in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any potential risk, and it is generally avoided in the third trimester. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Ibuprofen B. Braun offers the same COX‑inhibitory profile as oral ibuprofen but provides rapid, controlled plasma concentrations via intravenous administration. Compared with ketorolac, another IV NSAID, ibuprofen generally has a lower risk of severe gastrointestinal bleeding but may require higher doses for equivalent analgesia.

The injectable solution must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the vial for particulate matter and ensure the solution is at room temperature if required by the administration protocol.

Ibuprofen B. Braun is administered intravenously by slow infusion, typically over 15‑30 minutes, depending on the prescribed dose and clinical setting. Administration should be performed by qualified healthcare personnel using aseptic technique and appropriate IV equipment.

The most serious risks include severe bleeding (especially when combined with anticoagulants), acute kidney injury, and rare but life‑threatening hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt recognition and discontinuation are essential if these events occur.

Patients with known hypersensitivity to ibuprofen or any NSAID, those with active gastrointestinal bleeding, severe renal impairment, uncontrolled hypertension, or aspirin‑sensitive asthma should avoid this product. It is also contraindicated in the third trimester of pregnancy unless clearly indicated by a physician.